Genentech/OSI Tarceva Sales Force Hiring "Essentially Complete"
This article was originally published in The Pink Sheet Daily
Executive Summary
Ninety percent of new sales force hires are coming from outside the company, Genentech says. Wholesaler agreements are being finalized ahead of lung cancer agent's Jan. 30 user fee date.
You may also be interested in...
Genentech/OSI's Tarceva Will Be Detailed Alongside Herceptin
Tarceva approval comes just three-and-a-half months after application is completed and more than two months ahead of review deadline. Genentech and OSI will begin detailing the non-small cell lung cancer product immediately.
Genentech/OSI's Tarceva Will Be Detailed Alongside Herceptin
Tarceva approval comes just three-and-a-half months after application is completed and more than two months ahead of review deadline. Genentech and OSI will begin detailing the non-small cell lung cancer product immediately.
Tarceva Sales Effort Will Be Led By Genentech; OSI To Provide 25% Of Reps
An amendment to the companies' 2001 Tarceva development and marketing agreement clarifies responsibilities for each party upon FDA approval of the oncologic. OSI will be responsible for manufacturing commercial supply; the company plans to outsource production to third parties.